Construction and Characterization of a Novel Superantigen Fusion Protein: bFGF/SEB

REFERENCES

• White J., Herman A., Pullen A. M., et al. Vβ -specific superantigen SEB stimulation of mature T-cells and clonal deletion in neonatal mice. Cell 1989; 56: 27–35
   PubMed Web of Science ®Google Scholar
• Hedlund G., Dohlsten M., Petersson C., et al. Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother 1993; 36(2)89
   PubMed Web of Science ®Google Scholar
• Fleischer B., Schrezenmeier H. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 1988; 167(5)1697–1707
   Google Scholar
• Choi Y. W., Herman A., DiGiusto D., et al. Residues of the variable region of the T-cell-receptor beta-chain that interact with S. aureus toxin superantigens. Nature 1990; 346(6283)471–473
   PubMed Web of Science ®Google Scholar
• Kappler J., Kotzin B., Herron L., et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science 1989; 244(4906)811–813
   PubMed Web of Science ®Google Scholar
• Kalland T., Hedlund G., Dohlsten M., Lando P. A. Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1991; 174: 81–92
   PubMedGoogle Scholar
• Mondal T. K., Bhatta D., Biswas S., Pal P. Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines, and nitric oxide. Biochem Biophys Res Commun 2002; 290(4)1336–1342
   PubMed Web of Science ®Google Scholar
• Mehindate K., Thibodeau J., Dohlsten M., et al. Crosslinking of major histocompatibility comlex class molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med 1995; 182(5)1573–1577
   PubMed Web of Science ®Google Scholar
• Fischer H., et al. Production of TNF-α and TNF-β by staphylococcal enterotoxin A-activated human T cells. J Immunol 1990; 174(1)4663
   Google Scholar
• Sundstedt A., Hoiden I., Hansson J., et al. Superantigen -induced anergy in cytotoxic CD8+ T cells. J Immunol 1995; 154(12)6306–6313
   PubMed Web of Science ®Google Scholar
• Schliever P. M. Role of superantigens in human disease. J Infect Dis 1993; 167(5)997
   PubMed Web of Science ®Google Scholar
• Dohlsten M., Hedlund G., Akerblom E., Lando P. A., Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci USA 1991; 88(20)9287–9291
   PubMed Web of Science ®Google Scholar
• Litton M. J., Dohlsten M., Lando P., et al. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, exceesive cytokine, production and apoptosis in human colon carcinoma. Eur J Immunol 1996; 26: 1–9
   PubMed Web of Science ®Google Scholar
• Gidlof C., Dohlsten M., Lando P., et al. A superantigen antibody fusion protein for T cell immunotherapy of human B-lineage malignancies. Blood 1997; 89(6)2089
   PubMed Web of Science ®Google Scholar
• Ueno A., Arakawa F., Abe H., et al. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res 2002; 22(2A)769–776
   PubMed Web of Science ®Google Scholar
• Jennifer Wahlsten L., Charles D., et al. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. Immunology 1998; 161: 6761–6767
   Web of Science ®Google Scholar
• Kodama H., Suzuki M., Katayose Y., et al. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma. Cancer Immunol Immunother 2001; 50(10)539–548
   PubMed Web of Science ®Google Scholar
• Dickson C., Spencer-Dene B., Dillon C., et al. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2000; 2(3)191–196
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B., Ozen M., Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11(4)709–724
   PubMed Web of Science ®Google Scholar
• Gowardhan B., Douglas D. A., Mathers M. E., et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005; 92(2)320–327
   PubMed Web of Science ®Google Scholar
• Ozen M., Medrano E. E., Ittmann M. Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. Melanoma Res 2004; 14(1)13–21
   PubMed Web of Science ®Google Scholar
• Cronauer M. V., Schulz W. A., Seifert H. H., et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003; 43(3)309–319
   PubMed Web of Science ®Google Scholar
• Kuhn H., Kopff C., Konrad J., et al. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 2004; 44(2)167–174
   PubMed Web of Science ®Google Scholar
• Auguste P., Gursel D. B., Lemiere S., et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth y both angiogenesis-dependent and independent mechanisms. Cancer Res 2001; 1(4)1717–1726
   Google Scholar
• Galzie Z., Fernig D. G., Smith J. A., et al. Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factor. Int J Cancer 1997; 1(3)390–395
   Google Scholar
• Zhang H. J, Zhang S. M., Zhuang H., Lu F. M. Cytotoxicity of a novel fibroblast growth factor recptor targeted immunotoxin on human ovarian teraocarcinoma cell line. Cancer Biother Radiopharm 2006; 21(4)321–332
   PubMed Web of Science ®Google Scholar
• Wang L. H., Zhang S. M., Yu M. O., Yang X. I. Prokaryotic expression of superantigen Staphylococcal enterotoxin B. Clin J Microbiol Immunol 2006; 26(5)418–421
   Google Scholar
• Li J., Sun Y., Masako C., Li F., Alan G. Anti-tumor effects of mouse factor VII-Staphylococcus enterotoxin A (mfVII) chimeric protein in mice. Clin J Tumor 2005; 27(8)471–474
   Google Scholar
• Lappi D. A., Maher P. A., Martineau D., et al. The basic fibroblast growth factor, saporin mitotoxin, acts through the basic fibroblast growth factor receptor. J Cell Physiol 1991; 147: 17
   PubMed Web of Science ®Google Scholar
• Powers C. J., McLeskey S. W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165
   PubMed Web of Science ®Google Scholar
• Dohlsten M., Hansson J., Ohlsson L., et al. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci 1995; 92(21)9791–9795
   PubMed Web of Science ®Google Scholar
• Herrmann T., MacDonald H. R. The CD8+ T cell response to Staphylococcal enterotoxins. Semin Immunol 1993; 5(1)33–39
   PubMedGoogle Scholar
• Alexander R., Karin K., Johan H., et al. Perforin and IFN-γ are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 1998; 160: 5309–5311
   PubMed Web of Science ®Google Scholar